Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Durie

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
The Journal of Experimental Medicine|March 29, 2007
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathyRadek Spisek, Anjli Kukreja, Lin-Chi Chen, et al.
Cancers|April 3, 2021
Monocyte Subsets and Serum Inflammatory and Bone-Associated Markers in Monoclonal Gammopathy of Undetermined Significance and Multiple MyelomaDaniela Damasceno, Julia Almeida, Cristina Teodosio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2010
Survival and years of life lost in different age cohorts of patients with multiple myelomaHeinz Ludwig, Vanessa Bolejack, John Crowley, et al.
Blood|February 5, 2011
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2Nikhil C Munshi, Kenneth C Anderson, P Leif Bergsagel, et al.
Blood|February 5, 2011
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1S Vincent Rajkumar, Jean-Luc Harousseau, Brian Durie, et al.
Haematologica|January 18, 2024
Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 studySlavisa Ninkovic, Simon J Harrison, Je-Jung Lee, et al.
Blood Cancer Journal|October 10, 2019
Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma NetworkCinnie Yentia Soekojo, Kihyun Kim, Shang-Yi Huang, et al.
Annals of Hematology|February 8, 2019
Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registriesVania T M Hungria, Jae Hoon Lee, Angelo Maiolino, et al.
Blood Cancer Journal|December 3, 2021
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentageCarlos Fernández de Larrea, Robert Kyle, Laura Rosiñol, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 10, 2018
Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American CountriesRoberto José Pessoa de Magalhães Filho, Edvan Crusoe, Eloisa Riva, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
The Journal of Experimental Medicine|March 29, 2007
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathyRadek Spisek, Anjli Kukreja, Lin-Chi Chen, et al.
Cancers|April 3, 2021
Monocyte Subsets and Serum Inflammatory and Bone-Associated Markers in Monoclonal Gammopathy of Undetermined Significance and Multiple MyelomaDaniela Damasceno, Julia Almeida, Cristina Teodosio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2010
Survival and years of life lost in different age cohorts of patients with multiple myelomaHeinz Ludwig, Vanessa Bolejack, John Crowley, et al.
Blood|February 5, 2011
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2Nikhil C Munshi, Kenneth C Anderson, P Leif Bergsagel, et al.
Blood|February 5, 2011
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1S Vincent Rajkumar, Jean-Luc Harousseau, Brian Durie, et al.
Haematologica|January 18, 2024
Carfilzomib, thalidomide, and dexamethasone are safe and effective in relapsed and/or refractory multiple myeloma: final report of the single-arm, multicenter, phase II ALLG MM018/AMN002 studySlavisa Ninkovic, Simon J Harrison, Je-Jung Lee, et al.
Blood Cancer Journal|October 10, 2019
Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma NetworkCinnie Yentia Soekojo, Kihyun Kim, Shang-Yi Huang, et al.
Annals of Hematology|February 8, 2019
Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registriesVania T M Hungria, Jae Hoon Lee, Angelo Maiolino, et al.
Blood Cancer Journal|December 3, 2021
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentageCarlos Fernández de Larrea, Robert Kyle, Laura Rosiñol, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 10, 2018
Analysis of Availability and Access of Anti-myeloma Drugs and Impact on the Management of Multiple Myeloma in Latin American CountriesRoberto José Pessoa de Magalhães Filho, Edvan Crusoe, Eloisa Riva, et al.
Pageof 4